|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From Unitat de Bioquímica, Departament de
Ciències Fisiol B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the
accumulation of long-lived CD5+ B lymphocytes. TPA
(12-O-tetradecanoylphorbol 13- acetate) and interleukin-4
(IL-4) inhibit apoptosis of B-CLL lymphocytes ex vivo. We used specific
inhibitors of protein kinase C (PKC), extracellular-regulated kinase
(ERK), and phosphatidylinositol 3-kinase (PI3-kinase) to study their
involvement in TPA- and IL-4-induced survival of B-CLL lymphocytes.
BisI, a specific inhibitor of PKC, induced apoptosis and inhibited the
antiapoptotic activity of TPA and IL-4. B-CLL cells have a basal PKC
activity that was increased by TPA but not by IL-4. TPA, but not IL-4,
induced ERK activation. However, the inhibition of ERK activation did
not affect the viability of B-CLL lymphocytes, demonstrating that this
pathway is not involved in their survival. Inhibition of PI3-kinase by
LY294002 induced apoptosis of B-CLL cells and inhibited the survival
effect of IL-4 and TPA. In addition, Akt, a downstream effector of
PI3-kinase activity, was phosphorylated by TPA and IL-4 in B-CLL cells,
though PI3-kinase had no effect on PKC-dependent phosphorylation of
Akt. Furthermore, the inhibition of PKC or PI3-kinase increased
dexamethasone- and fludarabine-induced apoptosis ex vivo in the
presence of survival factors. These results demonstrate that PKC and
PI3-kinase are involved in the survival of B-CLL cells and suggest that
inhibitors of these pathways could be combined with the drugs used in
the treatment of B-CLL.
(Blood. 2002;99:2969-2976) B-cell chronic lymphocytic leukemia (B-CLL) is
characterized by the accumulation of monoclonal CD5+ B
lymphocytes.1,2 Most circulating cells appear to be
nondividing, and the clonal excess of B cells results from decreased
apoptosis rather than increased proliferation.3
Apoptosis of B-CLL lymphocytes is regulated by several
cytokines.4 When B-CLL lymphocytes are placed in culture
medium, they undergo apoptosis,5 probably triggered by the
absence of survival factor(s) that are present in vivo. Candidate
survival factors that prevent apoptosis of B-CLL lymphocytes ex vivo
include interleukin-4 (IL-4),6,7 interferon Protein kinase pathways involved in the survival of several cell types
include protein kinase C (PKC), extracellular-regulated kinase (ERK),
and phosphatidylinositol 3-kinase (PI3-kinase)
pathways.22-24 The phorbol ester TPA
(12-O-tetradecanoylphorbol 13-acetate) and bryostatin, 2 structurally unrelated activators of PKC, have been described as
inhibitors of spontaneous and chemotherapy-induced apoptosis in B-CLL
lymphocytes.17,25-29 Activation of PKC triggers the ERK
pathway,30,31 and IL-4 induces PI3-kinase in various cell
types, including B lymphocytes.32
PI3-kinase is an important mediator of survival factors, protecting
many cell types from multiple apoptosis-inducing
stimuli.23,33 PI3-kinase phosphorylates the D-3 position
of phosphatidylinositol, phosphatidylinositol 4-phosphate, and
phosphatidylinositol 4,5-diphosphate. Kinases such as
3-phosphoinositide-dependent kinase 1 (PDK1) and Akt bind to these
phosphorylated intermediates through their pleckstrin homology domain.
PDK1, in turn, phosphorylates and activates Akt, which has an important
role in cell survival.23
The role of PKC, ERK, and PI3-kinase pathways in the control of the
apoptosis of B-CLL lymphocytes has not been reported. Here we used
specific inhibitors of these kinases to study their involvement in TPA-
and IL-4-induced survival of B-CLL lymphocytes. Our results indicate
that PKC and PI3-kinase pathways regulate survival in B-CLL cells.
Patients
Cytokines and chemical reagents
Isolation of B-CLL cells Peripheral blood lymphocytes from patients with B-CLL were obtained from the Hematopathology Unit at the Hospital Clinic, Barcelona, Spain. Mononuclear cells from heparinized peripheral blood were isolated by centrifugation on a Ficoll-Hypaque (Seromed, Berlin, Germany) gradient and cryopreserved in liquid nitrogen in the presence of 10% dimethyl sulfoxide.The purity of B-CLL samples was evaluated by flow cytometry. Briefly, 5 × 105 cells were washed in phosphate-buffered saline (PBS) and were incubated in 50 µL PBS with allophycocyanin (APC)-conjugated anti-CD3 and phycoerythrin (PE)-conjugated anti-CD19 (PharMingen, Becton Dickinson, Mountain View, CA) for 10 minutes in the dark. Cells were then diluted with PBS to a volume of 250 µL and analyzed with a FACSCalibur (Becton Dickinson). Data analysis was performed with CellQuest software (Becton Dickinson). To analyze sufficient numbers of cells, a live-gate in forward scatter versus CD3 was drawn, and at least 5 × 103 CD3+ cells were acquired. The percentage of CD3+ T cells in B-CLL samples ranged from 0.4% to 5% (mean, 2.2% ± 1.5%). Cell culture B-CLL lymphocytes were cultured immediately after thawing at a concentration of 0.5 to 5 × 106 cells/mL in RPMI 1640 culture medium supplemented with 2 mM glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin (Biological Industries, Kibbutz Beit Haemek, Israel), and 10% heat-inactivated fetal bovine serum (Gibco BRL, Paisley, Scotland) at 37°C in a humidified atmosphere containing 5% carbon dioxide.17 The viability of B-CLL cells before commencing the incubation ranged from 62% to 91% (mean, 77% ± 9%). Factors were added 2 hours after the beginning of the culture, and cells were incubated for the indicated periods of time.Flow cytometry analysis of phosphatidylserine exposure and cell membrane permeability Cell viability and the rate of apoptosis were determined simultaneously by double staining with fluorescein isothiocyanate (FITC)-conjugated annexin V (Bender MedSystem, Vienna, Austria) and PI, as described previously.34 Briefly, 2 × 105 B-CLL cells were washed in PBS and resuspended in 100 µL annexin V-binding buffer (10 mM HEPES, pH 7.4, 2.5 mM CaCl2, 140 mM NaCl) containing 0.2 µL (1 µg/mL) FITC-annexin V. After 15 minutes of incubation in the dark at room temperature, cells were diluted with 100 µL annexin V-binding buffer containing 1 µg/mL PI and were analyzed with a FACSCalibur (Becton Dickinson). Data analysis was performed with CellQuest software (Becton Dickinson). Cell viability was measured as the percentage of annexin V- and PI-negative cells.Protein kinase C activity Protein kinase C activity was analyzed in particulate fraction containing membrane-associated PKC, as previously described,35 with minor modifications. Briefly, B-CLL cell pellets were homogenized in 200 µL of 25 mM Tris-HCl, containing 4 mM EGTA, 2 mM EDTA, 5 mM dithiothreitol, 1 mM PMSF, 1 µg/mL pepstatin, 1 µg/mL leupeptin, 1 µg/mL aprotinin, and 1 mM benzamidine, at pH 7.5 (buffer A). After 20 minutes incubation at 4°C, B-CLL cells were homogenized by 20 strokes with a dounce homogenizer. After centrifugation at 100 000g for 1 hour at 4°C, the supernatant (representing the cytosolic fraction) was collected, and the pellet was resuspended in 150 µL buffer A supplemented with 1% Triton X-100. After incubating for 1 hour at 4°C, the suspension was centrifuged at 100 000g for 1 hour at 4°C. This second supernatant (particulate fraction) contained the membrane-associate PKC. The distribution of -tubulin was used to estimate the purity of
particulate fractions.
PKC activity was assayed in both fractions by measuring the
incorporation of 32P from ( Phosphorylation in intact cells Phosphorylation of PKC substrates in intact cells was analyzed as previously described.37 Briefly, B-CLL cells (5 × 106 cells for each condition) were washed 3 times with RPMI 1640 medium without phosphate (Biological Industries) and resuspended at 10 × 106 cells/mL in the same medium supplemented with 32P-Orthophosphate (Amersham) (200 µCi/mL [7.4 MBq/mL]) for 5 hours at 37°C. Free phosphorus was eliminated by washing 3 times with ice-cold PBS, and the cells were then incubated for the indicated times in the presence of different factors. Cells were harvested and immediately extracted with 100 µL of 100 mM Tris-HCl, pH 6.8, 0.5% Triton X-100, 2 mM EGTA, 10 mM sodium fluoride, 1 mM PMSF, 1 µg/mL pepstatin, 1 µg/mL leupeptin, 1 µg/mL aprotinin, and 1 mM benzamidine for 20 minutes at 4°C. The extract was heated at 100°C for 10 minutes and centrifuged at 13 000 rpm for 10 minutes. The same amount of cell extract was analyzed by 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 32P-labeled proteins were detected by autoradiography.Western blot analysis of protein phosphorylation B-CLL lymphocytes were incubated at a density of 5 × 106 cells/mL with factors for the indicated period of time, washed in ice-cold PBS, resuspended in lysis buffer containing 50 mM Tris-HCl pH 7.5, 1% Triton X-100, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM EDTA, 40 mM -glycerophosphate, 100 mM NaCl,
1 µg/mL pepstatin, 1 µg/mL leupeptin, 1 µg/mL aprotinin, 1 mM
benzamidine, and 1 mM PMSF, and incubated on ice for 5 to 10 minutes.
After a 1-minute vortex, cell debris was eliminated by centrifugation at 13 000 rpm for 15 minutes, supernatants were collected, and protein
concentrations were determined using the Micro BCA Protein assay
reagent kit (Pierce). For the detection of phosphorylated forms of
ERK-1/ERK-2 (ERK) and Akt, whole lysates (50 µg) were resolved by
10% SDS-PAGE, transferred to Immobilon-P membranes (Millipore,
Bedford, MA), and analyzed by Western blotting with specific antibodies
against phospho-ERK (Thr202/Tyr204) and phospho-Akt (Ser473) (New
England BioLabs, Beverly, MA). As a confirmation of equal loading and
transfer proteins, blots were stripped and reproved with antibodies
against ERK (Upstate Biotechnology, Lake Placid, NY). After binding
with horseradish peroxidase-conjugated secondary antibodies, blots
were visualized with the enhanced chemiluminescence detection
system (Amersham).
Statistical analysis Levels of significance between samples were assessed by analysis of variance (Fisher PLSD test).
PKC inhibition blocks the survival effect of TPA and IL-4 To study the involvement of PKC in the survival of B-CLL lymphocytes, we used Bisindolylmaleimide I (BisI), a specific inhibitor of PKC.38 Treatment of B-CLL cells with 5 µM BisI induced apoptosis in 7 of 10 patients analyzed (patients 3, 4, 6, 7, 9, 11, and 12) and inhibited the survival effect of TPA and IL-4 (Table 1). The induction of apoptosis by BisI in the absence of TPA or IL-4 suggested that in most cases basal PKC activity contributed to the survival of B-CLL cells. Therefore, we measured PKC activity in B-CLL cells. As shown in Figure 1A, B-CLL cells have a basal membrane-associated PKC activity that corresponds to 13% of the total PKC activity. This activity was completely blocked in the presence of 1 µM BisI, corroborating that it corresponds to PKC activity. Membrane-associated PKC was increased by TPA but not by IL-4. Furthermore, we analyzed the phosphorylation level of the 3 major PKC substrates in B-CLL cells: myristoylated alanine-rich PKC substrate (MARCKS), MARCKS-related protein (MRP), and leukocyte-specific protein 1.37,39 B-CLL cells have a basal level of phosphorylation of these substrates that was inhibited by BisI, increased by TPA, and not affected by IL-4 (Figure 1B).
Next, we analyzed the effect of BisI on the survival effect of TPA and
IL-4 in combination with 2 drugs used in the chemotherapy of B-CLL:
dexamethasone (DEX) and fludarabine (F). The results shown in Figure
2 correspond to 3 representative patients
from 10 analyzed. BisI slightly increased the dexamethasone- or
fludarabine-induced apoptosis of B-CLL cells, and it inhibited the
protective effect of TPA and IL-4. Taken together, these results
demonstrate that PKC activity is involved in the survival of B-CLL
lymphocytes.
Analysis of ERK signaling cascades in the survival of B-CLL cells ERK is involved in the inhibition of apoptosis in response to survival factors in various cell types.22,40 Thus, we examined the role of ERK in TPA- and IL-4-mediated survival of B-CLL cells. We first studied whether TPA and IL-4 induced the activation of ERK using specific antibodies against its phosphorylated form. ERK was phosphorylated after 15 minutes of incubation with TPA in the 7 patients analyzed (Figure 3A), and this effect was dependent on PKC activation because it was blocked by preincubation with BisI (Figure 3B). In contrast, IL-4 did not induce ERK-phosphorylation in the 7 patients analyzed. Then we analyzed the correlation between the effect of TPA on ERK phosphorylation and B-CLL survival. The dose-response for TPA-induced ERK phosphorylation showed that the phosphorylated forms of ERK were detected when cells were incubated with 10 nM TPA in the 4 patients analyzed (Figure 3C). In contrast, the protective effect of TPA on dexamethasone-induced apoptosis reached plateau levels at 1 nM (Figure 3D). Similar results were obtained on spontaneous and fludarabine-induced apoptosis (data not shown). Thus, much higher doses of TPA were needed to induce ERK phosphorylation than for survival of B-CLL cells.
To further investigate whether the ERK cascade plays a role in
TPA-induced B-CLL lymphocyte survival, we used a specific inhibitor of
MEK (mitogen of extracellular regulated kinase) activation, U0126,41,42 which at a dose of 1 µM inhibited ERK
activation (Figure 4A) but did not alter
the survival effect of TPA (Figure 4B). Similar results were obtained
using PD98059, a structurally unrelated inhibitor of ERK cascade. As
expected, neither U0126 nor PD98059 inhibited IL-4-induced survival in
the 7 patients analyzed (data not shown). Taken together, these results
indicate that ERK is not involved in the antiapoptotic effect of TPA
and IL-4 in B-CLL cells.
PI3-kinase pathway is involved in the survival of B-CLL cells PI3-kinase plays an important role in the suppression of apoptosis in many cell types.23 To study the role of PI3-kinase in the survival of B-CLL cells, we used LY294002, a specific inhibitor of this kinase.43 B-CLL cells from 8 patients were cultured for 48 hours with medium alone (control), TPA, or IL-4 in the presence or absence of 20 µM LY294002, a concentration that inhibits PI3-kinase,42 and the percentage of nonapoptotic cells was analyzed by flow cytometry. LY294002 triggered apoptosis in B-CLL lymphocytes in all the patients studied except for patient 8 (Table 2). In most cases, the viability of cells treated with TPA or IL-4 in the presence of LY294002 was higher than that corresponding to cells incubated with LY294002 alone, but it was lower than the viability of cells incubated with TPA or IL-4, except in patient 8, in whom viability in the presence of these factors was not decreased by LY294002, and in patient 1, in whom viability in the presence of IL-4 was not affected by LY294002 (Table 2).
In addition, dose-response experiments were performed in cells from
patients 1 and 3 (Figure 5). Cells were
incubated with increasing concentrations of LY294002, ranging from 2 to
50 µM for 48 hours. Cell cytotoxicity was dose-dependent, and the
IC50 was approximately 3 µM and 6 µM,
respectively. Analysis of caspase-3 activation and PARP cleavage
by Western blot showed that LY294002 activated caspase-3 in B-CLL
cells (data not shown).
PI3-kinase activates several downstream signal transduction pathways,
including Akt and p70S6-kinase. We analyzed the involvement of these
kinases on the survival of B-CLL cells. First, we studied Akt
phosphorylation in B-CLL cells and whether TPA and IL-4 induced its
phosphorylation. Akt phosphorylation was analyzed in samples obtained
from 8 patients. In all patients, phosphorylated Akt was not detected
in nonstimulated B-CLL cells. TPA (8 of 8 patients) and IL-4 (4 of 8 patients) induced Akt phosphorylation. Five representative cases are
shown in Figure 6. Furthermore, the
inhibition of PI3-kinase by LY294002 blocked the effect of IL-4 but did
not alter the effect TPA. Rapamycin, a specific inhibitor of the
activation of p70S6K, had no effect on the antiapoptotic activity of
TPA or IL-4 (data not shown), indicating that p70S6K and
rapamycin-dependent pathways are not involved in the survival of B-CLL
cells.
Next, we analyzed the effect of PI3-kinase inhibition on
chemotherapy-induced apoptosis of B-CLL cells. LY294002 had an additive effect on the apoptotic activity of fludarabine in 3 of the 4 patients
analyzed (Figure 7). However, the
inhibition of PI3-kinase had no effect on dexamethasone-induced
apoptosis (8 of 8 patients analyzed; data not shown). LY294002 also
reduced the viability of cells treated with dexamethasone or
fludarabine, in the presence of TPA or IL-4, except in patient 9, in
whom TPA blocked the apoptosis induced by LY294002 (Figure 7). The
effect of LY294002 was more pronounced for IL-4-induced survival than
for the antiapoptotic effect of TPA in most of the patients analyzed.
We examined the signal transduction pathways involved in the survival of B-CLL cells. Two of the most studied survival factors for B-CLL cells are TPA17,21,25-29 and IL-4.6,7,13,17-19 We used specific inhibitors of kinases involved in the control of apoptosis to analyze their role in the survival of B-CLL cells. The PKC inhibitor BisI induced apoptosis in B-CLL cells. It has been
reported that UCN-01, another PKC inhibitor, induces apoptosis in these
cells.44 These findings are consistent with the
observation that B-CLL cells have a basal level of PKC activity. In
addition, the survival activity of TPA depends on PKC activity because
BisI inhibits its antiapoptotic effect. Although IL-4 did not activate
PKC, BisI inhibited its survival effect, indicating that the basal PKC
activity present in B-CLL cells is necessary for the protective effect
of IL-4. The downstream elements of PKC-mediated survival pathway in
B-CLL cells may involve activation of the transcription factor
NF- TPA, but not IL-4, activated ERK in B-CLL cells. This activation was mediated by PKC, because it was completely blocked by BisI. However, the inhibition of ERK did not affect the survival effect of TPA. The activation of this protein kinase may have other roles in B-CLL lymphocytes. For instance, it may be involved in TPA-induced differentiation.46 The inability of IL-4 to induce ERK activation has been reported in other hematopoietic cells, and it could be attributed to the fact that IL-4 does not activate the Ras pathway in these cells.47 Interestingly, the PI3-kinase-specific inhibitor LY294002 induced
apoptosis in B-CLL cells. In agreement with these results B-CLL cells
have basal PI3-kinase activity (manuscript in preparation). Furthermore, the apoptotic effect of LY294002 was not completely prevented by IL-4 and TPA in many patients with B-CLL. PI3-kinase activity is important in IL-4-induced survival, which was almost blocked by LY294002 in most of the patients analyzed. Our results indicate that PI3-kinase is an important survival pathway for B-CLL
cells, and they are consistent with the finding that peritoneal CD5+ B cells from mice with targeted disruption of p85 One downstream effector of PI3-kinase is Akt/PKB, which is a major participant in cell survival.23 Akt phosphorylates and inactivates at least 2 proteins involved directly in the control of apoptosis, Bad55,56 and Caspase-9.57 Bad is not expressed in most B-CLL samples,58 and the phosphorylation of caspase-9 has not been analyzed in B-CLL cells. In addition to inactivating apoptosis-regulating proteins, Akt may control the expression of genes involved in cell survival. Thus, Akt phosphorylates 3 members of the Forkhead family of transcription factors,23 which are retained in the cytoplasm, thus impairing the transcription of proapoptotic genes such as FasL59 and Bim.60 We found that TPA and IL-4 induce phosphorylation of Akt in B-CLL cells. Although TPA induced Akt phosphorylation, this effect was independent of PI3-kinase. This suggests that PI3-kinase-dependent activation of Akt does not contribute to PKC-induced survival in B-CLL cells. Thus, we propose that the effect of LY294002 in basal conditions or in cells stimulated with TPA was caused by the inhibition of PI3-kinase and a downstream PI3-kinase-dependent signaling pathway but that it was likely independent of Akt activity. However, we cannot rule out the involvement of Akt in TPA-induced B-CLL cell survival. IL-4 induced Akt phosphorylation in 50% of the cases analyzed, and this phosphorylation depends on PI3-kinase, suggesting that this is one of the mechanisms by which the activation of PI3-kinase induces survival of these cells, as described in many other systems.23 In addition, several protein kinases downstream of PI3-kinase involved in cell survival have been described, including several isotypes of PKC54 and CISK/SGK3.61 The role of these pathways in the survival of B-CLL cells will be analyzed in the future. In conclusion, our results demonstrate that PI3-kinase and PKC play important roles in the survival of B-CLL cells. Because inhibition of these kinases increases chemotherapy-induced apoptosis ex vivo in the presence of survival factors, this finding could contribute to the design of new therapeutic strategies. For example, combinations of drugs used in the treatment of B-CLL with inhibitors of PKC or PI3-kinase should be considered. Finally, the elucidation of the downstream components of the PI3-kinase and PKC pathways in the survival of B-CLL cells may suggest new pharmacologic targets for B-CLL therapy.
We thank Dra M. Dalmau for technical support in flow cytometry analysis. We also thank Dra E. Castaño, Dra M. Piqué, Dr F. Vinyals, Dr J. M. López-Blanco, D. Iglesias, and Dra N. Villamor for comments, helpful discussions, and suggestions, and R. Rycroft for language assistance.
Submitted May 10, 2001; accepted November 21, 2001.
Supported by grants from the Ministerio de Ciencia y Tecnología (SAF 98-0100 and SAF2001-3026) (J.G.). M.B., B.B., and C.C. are recipients of a research fellowship from the Ministerio de Ciencia y Tecnología, the Instituto de Salud Carlos III, and the Fundación Ramón Areces, respectively.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Joan Gil, Departament de Ciències Fisiològiques II, Campus de Bellvitge, Universitat de Barcelona, c/Feixa Llarga s/n, E-08907 L'Hospitalet de Llobregat, Spain; e-mail: joangil{at}bellvitge.bvg.ub.es.
1. Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol. 1998;5:244-253[Medline] [Order article via Infotrieve]. 2. Keating MJ. Chronic lymphocytic leukemia. Semin Oncol. 1999;26:107-114[Medline] [Order article via Infotrieve]. 3. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol. 1998;25:11-18[Medline] [Order article via Infotrieve]. 4. Jurlander J. The cellular biology of B-cell chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 1998;27:29-52[Medline] [Order article via Infotrieve]. 5. Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JF. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol. 1989;71:343-350[Medline] [Order article via Infotrieve].
6.
Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M.
Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression.
J Exp Med.
1992;176:1319-1326 7. Panayiotidis P, Ganeshaguru K, Jabbar SA, Hoffbrand AV. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1993;85:439-445[Medline] [Order article via Infotrieve].
8.
Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK.
Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia.
J Exp Med.
1993;177:213-218 9. Panayiotidis P, Ganeshaguru K, Jabbar SA, Hoffbrand AV. Alpha-interferon (alpha-IFN) protects B-chronic lymphocytic leukaemia cells from apoptotic cell death in vitro. Br J Haematol. 1994;86:169-173[Medline] [Order article via Infotrieve]. 10. Huang RW, Tsuda H, Takatsuki K. Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells. Int J Hematol. 1993;58:83-92[Medline] [Order article via Infotrieve]. 11. Reittie JE, Yong KL, Panayiotidis P, Hoffbrand AV. Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk Lymphoma. 1996;22:83-90[Medline] [Order article via Infotrieve].
12.
Francia di Celle P, Mariani S, Riera L, Stacchini A, Reato G, Foa R.
Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion.
Blood.
1996;87:4382-4389
13.
Chaouchi N, Wallon C, Goujard C, et al.
Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis.
Blood.
1996;87:1022-1029
14.
Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ.
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.
Blood.
2000;96:2655-2663
15.
Francia di Celle P, Carbone A, Marchis D, et al.
Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein.
Blood.
1994;84:220-228
16.
Mainou-Fowler T, Miller S, Proctor SJ, Dickinson AM.
The levels of TNF
17.
Bellosillo B, Dalmau M, Colomer D, Gil J.
Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells.
Blood.
1997;89:3378-3384
18.
Mainou-Fowler T, Craig VA, Copplestone JA, Hamon MD, Prentice AG.
Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitro independently of bcl-2 expression and is inhibited by IL-4.
Blood.
1994;84:2297-2304
19.
Fluckiger AC, Durand I, Banchereau J.
Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells.
J Exp Med.
1994;179:91-99
20.
Mentz F, Mossalayi MD, Ouaaz F, et al.
Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells.
Blood.
1996;88:2172-2182
21.
Byrd JC, Shinn C, Waselenko JK, et al.
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Blood.
1998;92:3804-3816 22. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM. Serine/threonine protein kinases and apoptosis. Exp Cell Res. 2000;256:34-41[CrossRef][Medline] [Order article via Infotrieve].
23.
Datta SR, Brunet A, Greenberg ME.
Cellular survival: a play in three Akts.
Genes Dev.
1999;13:2905-2927 24. O'Gorman DM, Cotter TG. Molecular signals in anti-apoptotic survival pathways. Leukemia. 2001;15:21-34[CrossRef][Medline] [Order article via Infotrieve]. 25. O'Connor TW. Phorbol ester-induced loss of colchicine ultrasensitivity in chronic lymphocytic leukaemia lymphocytes. Leuk Res. 1985;9:885-895[CrossRef][Medline] [Order article via Infotrieve]. 26. McConkey DJ, Aguilar-Santelises M, Hartzell P, et al. Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J Immunol. 1991;146:1072-1076[Abstract]. 27. Forbes IJ, Zalewski PD, Giannakis C, Cowled PA. Induction of apoptosis in chronic lymphocytic leukemia cells and its prevention by phorbol ester. Exp Cell Res. 1992;198:367-372[CrossRef][Medline] [Order article via Infotrieve].
28.
Robertson LE, Chubb S, Meyn RE, et al.
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine.
Blood.
1993;81:143-150 29. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;106:995-1004[CrossRef][Medline] [Order article via Infotrieve]. 30. Kolch W, Heidecker G, Kochs G, et al. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature. 1993;364:249-252[CrossRef][Medline] [Order article via Infotrieve].
31.
Schönwasser DC, Marais RM, Marshall CJ, Parker PJ.
Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes.
Mol Cell Biol.
1998;18:790-798 32. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999;17:701-738[CrossRef][Medline] [Order article via Infotrieve].
33.
Yao R, Cooper GM.
Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor.
Science.
1995;267:2003-2006
34.
Bellosillo B, Piqué M, Barragán M, et al.
Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells.
Blood.
1998;92:1406-1414 35. Colomer D, Vives-Corrons JLL, Bartrons R. Effect of TPA on fructose 2,6-bisphosphate levels and protein kinase C activity in B-chronic lymphocytic leukemia (B-CLL). Biochim Biophys Acta. 1991;1097:270-274[Medline] [Order article via Infotrieve]. 36. Chen SJ, Klann E, Gower MC, Powell CM, Sessoms JS, Sweatt JD. Studies with synthetic peptide substrates derived from the neuronal protein neurogranin reveal structural determinants of potency and selectivity for protein kinase C. Biochemistry. 1993;32:1032-1039[CrossRef][Medline] [Order article via Infotrieve]. 37. Carballo E, Colomer D, Vives CJ, Blackshear PJ, Gil J. Phosphorylation of the MARCKS family of protein kinase C substrates in human B chronic lymphocytic leukemia cells. Leukemia. 1995;9:834-839[Medline] [Order article via Infotrieve].
38.
Toullec D, Pianetti P, Coste H, et al.
The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.
J Biol Chem.
1991;266:15771-15781 39. Carballo E, Colomer D, Vives-Corrons JL, Blackshear PJ, Gil J. Characterization and purification of a protein kinase C substrate in human B cells: identification as lymphocyte-specific protein 1 (LSP1). J Immunol. 1996;156:1709-1713[Abstract].
40.
Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME.
Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.
Science.
1995;270:1326-1331
41.
Favata MF, Horiuchi KY, Manos EJ, et al.
Identification of a novel inhibitor of mitogen-activated protein kinase kinase.
J Biol Chem.
1998;273:18623-18632 42. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95-105[CrossRef][Medline] [Order article via Infotrieve].
43.
Vlahos CJ, Matter WF, Hui KY, Brown RF.
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).
J Biol Chem.
1994;269:5241-5248
44.
Kitada S, Zapata JM, Andreeff M, Reed JC.
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.
Blood.
2000;96:393-397
45.
Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ.
Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.
J Immunol.
2000;164:2200-2206 46. Tötterman TH, Nilsson K, Sundström C. Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells. Nature. 1980;288:176-178[CrossRef][Medline] [Order article via Infotrieve].
47.
Ueno H, Sasaki K, Honda H, et al.
c-Cbl is tyrosine-phosphorylated by interleukin-4 and enhances mitogenic and survival signals of interleukin-4 receptor by linking with the phosphatidylinositol 3'-kinase pathway.
Blood.
1998;91:46-53
48.
Suzuki H, Terauchi Y, Fujiwara M, et al.
Xid-like immunodeficiency in mice with disruption of the p85
49.
Fruman DA, Snapper SB, Yballe CM, et al.
Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85
50.
Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN.
Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase.
Proc Natl Acad Sci U S A.
1997;94:3627-3632
51.
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB.
NF-
52.
Wright K, Kolios G, Westwick J, Ward SG.
Cytokine-induced apoptosis in epithelial HT-29 cells is independent of nitric oxide formation: evidence for an interleukin-13-driven phosphatidylinositol 3-kinase-dependent survival mechanism.
J Biol Chem.
1999;274:17193-17201
53.
Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML.
Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways.
J Biol Chem.
1999;274:23013-23019
54.
Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ.
Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1.
Science.
1998;281:2042-2045
55.
del Peso L, González-García M, Page C, Herrera R, Nuñez G.
Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.
Science.
1997;278:687-689 56. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241[CrossRef][Medline] [Order article via Infotrieve].
57.
Cardone MH, Roy N, Stennicke HR, et al.
Regulation of cell death protease caspase-9 by phosphorylation.
Science.
1998;282:1318-1321
58.
Kitada S, Andersen J, Akar S, et al.
Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses.
Blood.
1998;91:3379-3389 59. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 1999;96:857-868[CrossRef][Medline] [Order article via Infotrieve]. 60. Dijkers PF, Medemadagger RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol. 2000;10:1201-1204[CrossRef][Medline] [Order article via Infotrieve]. 61. Liu D, Yang X, Songyang Z. Identification of CISK, a new member of the SGK kinase family that promotes IL-3-dependent survival. Curr Biol. 2000;10:1233-1236[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. Niedermeier, B. T. Hennessy, Z. A. Knight, M. Henneberg, J. Hu, A. V. Kurtova, W. G. Wierda, M. J. Keating, K. M. Shokat, and J. A. Burger Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach Blood, May 28, 2009; 113(22): 5549 - 5557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Ghosh, N. E. Kay, C. R. Secreto, and T. D. Shanafelt Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG Clin. Cancer Res., February 15, 2009; 15(4): 1250 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Balakrishnan, J. A. Burger, W. G. Wierda, and V. Gandhi AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance Blood, January 1, 2009; 113(1): 149 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bekeredjian-Ding, A. Doster, M. Schiller, P. Heyder, H.-M. Lorenz, B. Schraven, U. Bommhardt, and K. Heeg TLR9-Activating DNA Up-Regulates ZAP70 via Sustained PKB Induction in IgM+ B Cells J. Immunol., December 15, 2008; 181(12): 8267 - 8277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hewamana, T. T. Lin, C. Jenkins, A. K. Burnett, C. T. Jordan, C. Fegan, P. Brennan, C. Rowntree, and C. Pepper The Novel Nuclear Factor-{kappa}B Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine Clin. Cancer Res., December 15, 2008; 14(24): 8102 - 8111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Veldurthy, M. Patz, S. Hagist, C. P. Pallasch, C.-M. Wendtner, M. Hallek, and G. Krause The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes Blood, August 15, 2008; 112(4): 1443 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Plate Signals that maintain leukemic cell viability Blood, July 1, 2008; 112(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
|
|
S. Hewamana, S. Alghazal, T. T. Lin, M. Clement, C. Jenkins, M. L. Guzman, C. T. Jordan, S. Neelakantan, P. A. Crooks, A. K. Burnett, et al. The NF-{kappa}B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target Blood, May 1, 2008; 111(9): 4681 - 4689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. O'Brien New Agents in the Treatment of CLL Hematology, January 1, 2008; 2008(1): 457 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Liu, X. Zhao, F. Frissora, Y. Ma, R. Santhanam, D. Jarjoura, A. Lehman, D. Perrotti, C.-S. Chen, J. T. Dalton, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma Blood, January 1, 2008; 111(1): 275 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Abrams, T. Lakum, K. Lin, G. M. Jones, A. T. Treweeke, M. Farahani, M. Hughes, M. Zuzel, and J. R. Slupsky B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase C{beta}II Blood, February 1, 2007; 109(3): 1193 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Barragan, M. de Frias, D. Iglesias-Serret, C. Campas, E. Castano, A. F. Santidrian, L. Coll-Mulet, A. M. Cosialls, A. Domingo, G. Pons, et al. Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta} J. Leukoc. Biol., December 1, 2006; 80(6): 1473 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Coll-Mulet, D. Iglesias-Serret, A. F. Santidrian, A. M. Cosialls, M. de Frias, E. Castano, C. Campas, M. Barragan, A. F. de Sevilla, A. Domingo, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells Blood, May 15, 2006; 107(10): 4109 - 4114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nakagawa, J. W. Soh, and A. M. Michie Subversion of Protein Kinase C{alpha} Signaling in Hematopoietic Progenitor Cells Results in the Generation of a B-Cell Chronic Lymphocytic Leukemia-Like Population In vivo Cancer Res., January 1, 2006; 66(1): 527 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Secchiero, E. Barbarotto, A. Gonelli, M. Tiribelli, C. Zerbinati, C. Celeghini, C. Agostinelli, S. A. Pileri, and G. Zauli Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells Am. J. Pathol., December 1, 2005; 167(6): 1599 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nishio, T. Endo, N. Tsukada, J. Ohata, S. Kitada, J. C. Reed, N. J. Zvaifler, and T. J. Kipps Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1{alpha} Blood, August 1, 2005; 106(3): 1012 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Petlickovski, L. Laurenti, X. Li, S. Marietti, P. Chiusolo, S. Sica, G. Leone, and D. G. Efremov Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells Blood, June 15, 2005; 105(12): 4820 - 4827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Harris, B. Ozpolat, F. Abdi, S. Gu, A. Legler, K. G. Mawuenyega, M. Tirado-Gomez, G. Lopez-Berestein, and X. Chen Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia Blood, September 1, 2004; 104(5): 1314 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. K. Lee, N. D. Bone, A. K. Strege, T. D. Shanafelt, D. F. Jelinek, and N. E. Kay VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia Blood, August 1, 2004; 104(3): 788 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Decker, M. Oelsner, R. J. Kreitman, G. Salvatore, Q.-c. Wang, I. Pastan, C. Peschel, and T. Licht Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins Blood, April 1, 2004; 103(7): 2718 - 2726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Mone, P. Huang, H. Pelicano, C. M. Cheney, J. M. Green, J. Y. Tso, A. J. Johnson, S. Jefferson, T. S. Lin, and J. C. Byrd Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells Blood, March 1, 2004; 103(5): 1846 - 1854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Campas, J. M. Lopez, A. F. Santidrian, M. Barragan, B. Bellosillo, D. Colomer, and J. Gil Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes Blood, May 1, 2003; 101(9): 3674 - 3680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pepper, A. Thomas, T. Hoy, D. Milligan, P. Bentley, and C. Fegan The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro Blood, April 1, 2003; 101(7): 2454 - 2459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ringshausen, F. Schneller, C. Bogner, S. Hipp, J. Duyster, C. Peschel, and T. Decker Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta Blood, November 15, 2002; 100(10): 3741 - 3748. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
(IFN-
) or the absence (
) of 5 µM BisI. After that
time, drugs were added to the culture, incubation continued for another
48 hours. At the end of the culture, cell viability was analyzed by
flow cytometry. Results are represented as the mean ± SD from one
experiment performed in duplicate.
), 2 (
), and 3 (
) were incubated for 48 hours with different doses of
TPA in the presence of 10 µM dexamethasone, and cell viability was
determined by flow cytometry. Results are represented as the mean ± SD from one experiment performed in duplicate.
B